Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 480 of 5804
-
Laser and Light-Sensitive drug aim to zap prostate cancer without surgery
Disease control Recruiting nowThe goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the treatment of primary localized prostate cancer. The st…
Phase: PHASE1, PHASE2 • Sponsor: SpectraCure AB • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug cocktail aims to shrink tough prostate tumors before surgery
Disease control Recruiting nowResearchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advan…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Higher buprenorphine dose may keep more people in opioid treatment
Disease control Recruiting nowThe investigators aim to test the effectiveness of a high maintenance daily dose of buprenorphine (24 mg) for improving outcomes among patients who used fentanyl compared to the standard daily dose (16 mg). The main question it aims to answer is: will patients who are randomly a…
Phase: PHASE2, PHASE3 • Sponsor: Rhode Island Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for advanced breast cancer: phase 3 trial launches
Disease control OngoingThe purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or prog…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Immunotherapy plus chemo shows promise against tough stomach cancer
Disease control OngoingThe goal of this clinical trial is to learn if FLOT chemotherapy combined with serplulimab can improve the pathological complete response (pCR) rate in patients with stage III gastric cancer. The main question it aims to answer is: Can FLOT chemotherapy combined with serplulimab…
Phase: PHASE2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for hard-to-treat ovarian cancer: targeted drug combo enters trial
Disease control Recruiting nowOvarian cancer exhibits the highest mortality rate among gynecological malignancies. Currently, the combination of paclitaxel and carboplatin remains the standard first-line chemotherapy regimen for neoadjuvant or postoperative treatment of ovarian cancer. However, conventional p…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for Tough-to-Treat blood cancers: pirtobrutinib trial launches
Disease control Recruiting nowThe main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosi…
Phase: PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New immunotherapy combo takes on advanced liver cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of Adabrelimab (arterial or intravenous administration) combined with hepatic artery FOLFOX infusion chemotherapy and Bevacizumab as the first-line treatment of advanced stage hepatocellular carcinoma. Patients will…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Promising new combo tackles tough leukemia
Disease control Recruiting nowThis phase II trial tests how well venetoclax with cladribine and cytarabine alternating with azacitidine and venetoclax works in treating patients with newly diagnosed monocytic acute myeloid leukemia (AML) and active signaling mutated AML. Venetoclax is in a class of medication…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Simple blood test could spot hidden heart risk in kids
Diagnosis Recruiting nowFamilial hypercholesterolemia is the most common treatable genetic disorder for which a simple, effective treatment is available, with few side effects. It leads to a significant increase in LDL levels, generally in excess of 1.9g/l, including in children. It is much higher than…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
New study aims to help At-Risk youth prevent HIV and get substance use support
Disease control Recruiting nowA randomized controlled trial to assess the ability of a Collaborative Care Prevention, Treatment, Navigation, Engagement, Resource (PrTNER) intervention to increase initiation of preexposure prophylaxis (PrEP) (for those at-risk for HIV) and decrease viral load (for those living…
Phase: NA • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo aims to heal gut in Crohn's patients
Disease control Recruiting nowThe main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely ac…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental CAR-T therapy targets tough blood cancers
Disease control Recruiting nowThis is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies. In the proposed trial, eligible enrolled participants will undergo leukapheresis f…
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Nasal spray could shrink polyps and reduce need for surgery
Disease control CompletedThe goal of this study is to evaluate whether a nasal spray containing adelmidrol, a mast cell modulator and precursor of palmitoylethanolamide, can reduce inflammation, improve symptoms, and decrease nasal polyp size in patients with chronic rhinosinusitis with nasal polyps. The…
Phase: NA • Sponsor: University of Campania Luigi Vanvitelli • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Brain zaps for war trauma? new TMS study hints at faster PTSD relief
Symptom relief CompletedPosttraumatic stress disorder (PTSD) among military service members and veterans is as high as 32% and is the third most service-connected disability, resulting in over $1.5 billion in direct costs over a five-year period. According to Clinical Practice Guidelines, strong evidenc…
Phase: NA • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
Stool test could spot stomach cancer before it spreads
Diagnosis OngoingBased on the detection technology of methylation sites in feces, combined or not combined with Helicobacter pylori gastric cancer susceptibility gene detection, an early diagnosis and detection system for gastric cancer is established, and the clinical diagnostic value of the det…
Sponsor: Fudan University • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
New hope for frail AML patients: less toxic drug combo shows promise
Disease control CompletedThis study aims to evaluate the efficacy and safety of selinexor-based chemotherapy-sparing regimens (including chemotherapy-free or dose-reduced approaches) in optimizing therapeutic strategies for treatment-naïve acute myeloid leukemia patients deemed unfit for intensive induct…
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New blood filter could save lives in septic shock
Disease control ENROLLING_BY_INVITATIONThere is a lack of evidence in the efficacy of extracorporeal blood purification (EBP) to reduce the mortality rate in septic shock. We have designed the EABPSS (Efficacy of Adaptive Blood Purification for Septic Shock) study to confirm whether adaptive blood purification (ABP) i…
Phase: NA • Sponsor: Beijing Chao Yang Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug duo aims to slash leukemia relapse after bone marrow transplant
Disease control Recruiting nowThis study aims to determine whether the recurrence rate of high-risk acute myeloid leukemia CR1 patients who received allogeneic hematopoietic stem cell transplantation with the Ruxolitinib, Decitabine combined with Bu/Cy or BuF intensive pretreatment regimen is reduced compared…
Phase: PHASE4 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can a lower drug dose prevent transplant complications just as well?
Disease control Recruiting nowThis is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg/kg combined with tacrolimus and post-engraftment low dose anti-thymoglobin (ATG) as graft versus host disease (GVHD) prophylaxis…
Phase: PHASE3 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC